Suhika
SuhikaAbout
What does Suhika do?
Suhika offers an AI Inbox Copilot for medical practices, specifically designed for care teams to manage patient WhatsApp messages. It helps triage, route, and draft responses to patient inquiries, grounding AI-generated replies in each patient's actual medical record. Every AI-drafted reply is reviewed by a human before being sent, ensuring clinical safety and efficiency for outpatient neurology practices, with plans to expand to other specialties.
Is Suhika trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Suhika is 58 out of 100, based on site security posture and privacy practices.
When was Suhika founded?
Suhika was founded in 2026.
What industry does Suhika operate in?
Suhika operates in HealthTech, Clinical Communication, Patient Engagement, AI Chatbot, Conversational AI, Workflow Automation.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
Leading AI agency in Guwahati specializing in biological intelligence, generative AI, and regulatory systems for Asia's underrepresented populations.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 5 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.